Waterhouse DM, Garon EB, Chandler J, et al. - Researchers compared the effect of 1-year fixed-duration vs continuous therapy on the effectiveness as well as safety of nivolumab in an exploratory analysis of a largely community-based phase IIIb/IV study, CheckMate 153. Nivolumab monotherapy (3 mg/kg every 2 weeks) was administered to patients with previously treated advanced NSCLC. A total of 1,428 patients were treated, and of those, 252 were randomized to continuous (n = 127) or 1-year fixed-duration (n = 125) treatment (intent-to-treat [ITT] population). A minimum post–random assignment follow-up of 13.5 months revealed that continuous therapy afforded longer median progression-free survival than 1-year fixed-duration treatment. These data are the first randomized data on continuous vs fixed-duration immunotherapy in previously treated advanced NSCLC. These results indicate that improved outcomes are achieved by continuing nivolumab beyond 1 year.